SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MEDX ... anybody following?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David W. Tucker who wrote (517)8/7/2000 12:08:58 PM
From: Exacctnt  Read Replies (1) of 2240
 
The CEO, Drakeman came across well. When asked how MEDX would be creating revenue, he responded that they will continue to receive fees on their mouse technology, as well as developing their own drug candidates. He said their technology allows them to initiate drug candidates into phase 1 category in 12 months instead of the pharmaceutical time line of up to 5 years. They plan on developing up to 12 drug candidates a year.

When asked about competition, he responded that the field is big enough for all to succeed. Barriers to entry for similar technology consist of 10's of millions of dollars to develop the technology, but more importantly, patents provide protection.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News